drugset
drugset / Trial / NCT05260008

Study Assessing Pain Relief After Replacement of the Knee

NCT05260008 ↗

Phase 2 Terminated 112 enrolled Allay Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 2B randomized, double blind, active controlled, multi-center clinical trial to evaluate the safety and efficacy of ATX-101 in participants following total knee arthroplasty. The following is short title and acronym for the study: Study Assessing Pain Relief after Replacement of the Knee (SPARK)

Timeline

Start
2022-06-07
Primary completion
2024-01-15
Completion
2024-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ATX-101 Peptide — Other
Comparator Bupivacaine Other / unclassified 125 mg Other

Indications

No indication recorded.